Lantheus Holdings Stock Plummets 23% in Three Days Amid Revenue Miss and 148th Highest Trading Volume

Generated by AI AgentAinvest Market Brief
Wednesday, May 7, 2025 8:00 pm ET1min read

Lantheus Holdings (LNTH) experienced a significant drop in its stock price, falling by 23.23% over the past three days, with a cumulative decline of 25.98%. The company's trading volume surged to $594 million, making it the 148th highest in the market for the day.

Lantheus reported its first-quarter 2025 financial results, revealing worldwide revenue of $372.8 million. The company's GAAP fully diluted earnings per share stood at $1.02, a decrease from $1.87 in the same period last year. The company's full-year revenue guidance was adjusted to $1.57 billion at the midpoint, which is 1.5% below analysts' estimates. Additionally, the non-GAAP profit of $1.53 per share was 7.5% below analysts' consensus estimates.

Lantheus' management has lowered its full-year Adjusted EPS guidance to $6.65 at the midpoint, a 6.3% decrease from previous estimates. The company's operating margin decreased to 27.4% from 28.8% in the same quarter last year, while the free cash flow margin dropped to 26.5% from 32.2%. The company's market capitalization is $7.19 billion.

Brian Markison, Chief Executive Officer at

, highlighted the company's strategic acquisitions, including Evergreen Theragnostics and the planned acquisition of Life Molecular Imaging. These acquisitions are expected to add growth drivers that complement Lantheus' business and diversify its revenues. The transactions also bring new pipeline programs in both late- and early-stage development, along with key capabilities that enable Lantheus to progress novel programs from bench to clinic.

Lantheus Holdings has shown impressive long-term sales performance, growing its sales at a compounded annual growth rate of 34.3% over the last five years. This growth rate exceeds the average healthcare company, indicating strong customer demand for its offerings. Over the last two years, Lantheus' annualized revenue growth was 22.3%, suggesting continued healthy demand despite a slight slowdown from its five-year trend.

Comments



Add a public comment...
No comments

No comments yet